Comparison the WHO classification and the International Consensus Classification for myelodysplastic syndromes/neoplasms and acute myeloid leukemia
10.3760/cma.j.cn114452-20240422-00205
- VernacularTitle:骨髓增生异常综合征/肿瘤和急性髓系白血病WHO分类和国际共识分类比较
- Author:
Yigang LIU
1
;
Huiting QU
;
Li LI
;
Jing WANG
;
Xiaosheng FANG
;
Qian WANG
;
Zie WANG
;
Hui SUN
;
Min HUANG
;
Jian ZHANG
;
Zhifen ZHANG
;
Xiaoling ZHEN
;
Wenbo ZHAO
;
Huanling WU
Author Information
1. 山东第一医科大学附属省立医院临床医学检验部，济南250021
- Keywords:
Hematologic neoplasms;
Leukemia;
WHO classification of hematopoietic and lymphoid tissue neoplasms;
International Consensus Classification;
Myelodysplasti
- From:
Chinese Journal of Laboratory Medicine
2024;47(8):844-851
- CountryChina
- Language:Chinese
-
Abstract:
The World Health Organization (WHO) classification serves as the internationally recognized standard for diagnosing and classifying hematopoietic and lymphoid tissue tumors(WHO-HEAM). Since 2001, it has undergone multiple upgrades and revisions, updating, clarifying, and refining previous tumor diagnostic and classification standards while incorporating numerous new genetic and molecular biological subtypes. In 2022, two classification proposals emerged due to a wealth of clinical and scientific research results: the fifth edition of the WHO hematopoietic and lymphoid tissue classification (WHO-HAEM5), published in Leukemia journal; and the International Consensus Classification (ICC), published in Blood journal. These two schemes differ in their approach to classifying hematopoietic and lymphoid tissue tumors, posing challenges for clinical laboratory diagnosis and treatment.
